Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline
    • SNDX-5613
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials
    • SNDX-5613 Clinical Trials
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
  • Contact Us
Syndax
Contact Us
  • About
  • Pipeline
  • Clinical Trials
  • Patients & Caregivers
  • Investors
  • Join Us

Determined to realize a future in which people with cancer live longer and better than ever before.


  • What is SNDX-5613?
  • What is axatilimab?
  • What is entinostat?
  • What clinical trials is Syndax currently conducting?
  • Who is on the leadership team at Syndax?
  • Where can I see your product pipeline?
  • What is the vision of Syndax?
  • Is Syndax hiring?
  • How can my organization collaborate with Syndax?
Pipeline
Leadership
Clinical Trials
Publications

04.15.21

Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias

04.08.21

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

03.31.21

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

03.08.21

Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

© 2021 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • Investors
  • Career Opportunities